A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Summary

This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 began. Stage 2 also evaluated the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease (DED), and assessed the plasma and tear exposure of both ophthalmic solutions.

Timeline

Start

2020-03-04

Primary completion

2022-03-18

Completion

2022-03-18

Drugs

Indications